Thrombotic thrombocytopenic purpura (TTP) is a serious complication following bone marrow transplantation (BMT). Therapeutic plasma exchange does not appear to be effective in its management in contrast to classical TTP. We report the case of a child with TTP 3 years after autologous PBSC transplantation, in whom remission was achieved by administration of cyclosporin A, after failure of plasmapheresis as primary treatment. Keywords: bone marrow transplant; peripheral blood stem cell transplant; thrombotic thrombocytopenic purpura; plasma exchange, cyclosporin A Thrombotic thrombocytopenic purpura (TTP), first described by Moschcowitz 1 in 1924, is a pentad comprising microangiopathic hemolytic anemia, thrombocytopenia, neurologic symptoms, fever and renal dysfunction. Predisposing factors are pregnancy, infections, collagen vascular disease, chemotherapy and organ transplantation. The incidence of TTP after bone marrow transplantation (BMT) is about 14% and 7% in allograft and autograft recipients, respectively.
Thrombotic thrombocytopenic purpura (TTP), first described by Moschcowitz 1 in 1924, is a pentad comprising microangiopathic hemolytic anemia, thrombocytopenia, neurologic symptoms, fever and renal dysfunction. Predisposing factors are pregnancy, infections, collagen vascular disease, chemotherapy and organ transplantation. The incidence of TTP after bone marrow transplantation (BMT) is about 14% and 7% in allograft and autograft recipients, respectively. 2 Several factors are important in the etiology, including cyclosporin A (CsA), graft-versus-host disease (GVHD), total body irradiation (TBI), intensive conditioning chemotherapy and opportunistic infections. In some reports, the use of CsA and occurrence of GVHD emerged as the only significant risk factors in post BMT-TTP, 3 although a recent study has reported CsA to be an interesting drug for post autologous BMT-TTP. 4 Although the reported interval between BMT and diagnosis of TTP has been reported to range from 4 days to 29 months, 2 we describe a patient who developed TTP very late (42 months) after PBSC. 
Case report
A 13-year-old girl was diagnosed with Hodgkin's disease stage IV B in November 1993. She was treated with MOPP-ABVD in alternate courses to a total of six, and achieved first remission in April 1994.
An autologous peripheral blood progenitor cell transplantation was scheduled 2 months later. She was conditioned with carmustine (600 mg/m 2 on day −5), cyclophosphamide (60 mg/kg on days −4 and −3) and etoposide (40 mg/kg on day −2).
In December 1997 she developed fever, malaise and bleeding. Physical examination showed jaundice and petechiae on the lower limbs. Thrombocytopenia (3 × 10 9 /l) and hemolytic anemia (hemoglobin 6 g/dl, lactate dehydrogenase 2545 U/l, total bilirubin 4.5 mg/dl, reticulocytes 65%, haptoglobin indetectable) with schistocytes in the blood smear were present. Direct and indirect Coombs tests were negative. Coagulation tests were normal.
Elevation of liver enzymes (GOT 120 U/l, GPT 313 U/l and GGT 122 U/l) occurred and renal parameters were: urea 47 mg/dl and creatinine 0.78 mg/dl.
Further diagnostic studies including tests for antinuclear antibodies and viral serology were negative. No antiplatelet antibodies were detected. Bone marrow biopsy showed good cellularity without signs of tumor infiltration, myelodysplasia or leukemia.
The patient then developed generalized seizures and secondary obnubilation and aphasia. A cranial CT scan was normal. A diagnosis of thrombotic thrombocytopenic purpura was made based on the findings of severe anemia, thrombocytopenia, red cell fragmentation, high levels of lactate dehydrogenase and neurological symptoms.
Plasma and intravenous immunoglobulin (400 mg/ kg/day) were started along with steroid therapy (2 mg/kg/day) for 3 days, and plasmapheresis was performed on day +3.
5 Plasma exchanges were performed for 7 days with a COBE Spectra (Lakewood, CO, USA) and plasma was replaced with cryoprecipitate-poor plasma, without resolution of hemolysis. At each session, a plasma volume of 50 cm 3 /kg was administered over a period of 4-5 h. Plasma exchange achieved poor results; platelet counts ranged from 2 × 10 9 /l to 20 × 10 9 /l and LDH levels ranged from 1043 to 1703 Ul during days 1-7 of plasmapheresis.
Vincristine 2 mg on days 1, 4, 7 and 10 was started but was discontinued on the second dose because she developed peripheral polyneuropathy. 6 The patient finally received immunosuppressive therapy with cyclosporin A (200 mg/day) and her platelet counts increased slowly after day +5. On day +10 she had recovered completely with a stable platelet count greater than 150 × 10 9 /l; LDH and hemoglobin levels returned to normal ranges. CsA was given for 6 months. To date (July 1998) there has been no relapse of the TTP.
Discussion
The pathogenesis of this disease is unclear, but there are three proposed pathological mechanisms. Firstly, a systemic disturbance of endothelial cells causes a defect in the processing of von Willebrand factor multimers, which are capable of binding to the platelet receptors GP Ib and GP IIb/IIIa and inducing systemic platelet aggregation. 7 Secondly, decreased synthesis of prostaglandin I 2 (PGI 2 ) by the endothelium leads to widespread microthrombi in various organs (brain, kidney, liver and heart). 8 Thirdly, low levels of protein C in plasma have been postulated. 9 In classical TTP, therapeutic plasma exchange with cryosupernatant plasma has achieved high rates of remission and has reduced the mortality from 90% to 20%. However, plasma exchange does not appear to be effective in the management of TTP following BMT, 10 as we observed in our patient. Plasma infusion can be initiated at a dose of 30 cm 3 /kg/day before plasmapheresis. The lack of response to plasmapheresis in post BMT-TTP in contrast to excellent responses in classical TTP, may indicate different pathological mechanisms. In bone marrow recipients, several risk factors for TTP have been proposed such as: previous treatment with high-dose chemotherapy and TBI, opportunistic infections, GVHD and CsA therapy. None of the foregoing were found in our patient except for high-dose chemotherapy, to which post autologous BMT-TTP is difficult to ascribe since it appeared very late. In secondary TTP after BMT, vascular damage may be caused by cellular rather than soluble factors and this is less likely to be ameliorated by plasma exchange. 2 Although the only risk factor found in our patient was high-dose chemotherapy, we believe that this is a case of late post-autologous BMT-TTP because of the patient's clinical characteristics and because she did not respond to plasmapheresis but responded to treatment with CsA as described elsewhere. 4 Concerning platelet replacement, there are several reports that show an exacerbation of the thrombotic process in the microcirculation after platelet transfusion. 11 Platelet substitution may be necessary in cases with very severe bleeding. Our patient did not receive transfusions, although she did have a low platelet count.
The effective treatment of post-autologous BMT-TTP with CsA, as previously reported, 4 seems to be in contrast to data showing the thrombotic effect of CsA that causes TTP in recipients of allogeneic BMT. 3 The results achieved with CsA in the case described here support the findings reported by Van Ojik and co-workers. Its efficacy might be explained by the capability of CsA to stimulate endothelial nitric oxide activity, which inhibits platelet aggregation, and by its immunosuppressive action. 4 
